Method and circuit for indicating quality and accuracy of physiological measurements

Information

  • Patent Grant
  • 8133176
  • Patent Number
    8,133,176
  • Date Filed
    Friday, September 30, 2005
    18 years ago
  • Date Issued
    Tuesday, March 13, 2012
    12 years ago
Abstract
Sensors and monitors for a physiological monitoring system having capability to indicate an accuracy of an estimated physiological condition. The sensor senses at least one physiological characteristic of a patient and is connectable to a monitor that estimates the physiological condition from signals detected by the sensor. The sensor includes a detector for detecting the signals from the patient which are indicative of the physiological characteristic. The sensor is associated with a memory configured to store data that defines at least one sensor signal specification boundary for the detected signals. The boundary is indicative of a quality of the signals and an accuracy of the physiological characteristic estimated from the signals by the monitor. The sensor further includes means for providing access to the memory to allow transmission of the data that defines the at least one sensor boundary to the monitor.
Description
BACKGROUND OF THE INVENTION

The present invention relates to physiological monitoring instruments and, in particular, monitors and sensors that include mechanisms for indicating a quality of detected signals and accuracy or confidence level of physiological measurements estimated from the signals.


Typically, for physiological monitoring instruments that include a monitor and a patient sensor, the monitor is unable to accurately determine a quality of a signal obtained from the sensor. The invention will be explained by reference to a preferred embodiment concerning pulse oximeter monitors and pulse oximetry sensors, but it should be realized the invention is applicable to any generalized patient monitor and associated patient sensor. The invention provides a way of more accurately determining a quality of a signal detected by a sensor; a way of determining a relative accuracy of a physiological characteristic derived or calculated from the signal; and a way of delineating a transition boundary between a normal signal for the sensor being used in its normal application, and a signal considered to be abnormal for the sensor being used, to allow a monitor to determine if the sensor is being misapplied.


Pulse oximetry is typically used to measure various blood flow characteristics including, but not limited to, the blood oxygen saturation of hemoglobin in arterial blood and the heartbeat of a patient. Measurement of these characteristics has been accomplished by the use of a non-invasive sensor that passes light through a portion of a patient's blood perfused tissue and photo-electrically senses the absorption and scattering of light in such tissue. The amount of light absorbed and scattered is then used to estimate the amount of blood constituent in the tissue using various algorithms known in the art. The “pulse” in pulse oximetry comes from the time varying amount of arterial blood in the tissue during a cardiac cycle. The signal processed from the sensed optical signal is a familiar plethysmographic waveform due to the cycling light attenuation.


The light passed through the tissue is typically selected to be of two or more wavelengths that are absorbed by the blood in an amount related to the amount of blood constituent present in the blood. The amount of transmitted light that passes through the tissue varies in accordance with the changing amount of blood constituent in the tissue and the related light absorption.


To estimate arterial blood oxygen saturation of a patient, conventional two-wavelength pulse oximeters emit light from two light emitting diodes (LEDs) into a pulsatile tissue bed and collect the transmitted light with a photodiode (or photo-detector) positioned on an opposite surface (i.e., for transmission pulse oximetry) or an adjacent surface (i.e., for reflectance pulse oximetry). The LEDs and photo-detector are typically housed in a reusable or disposable oximeter sensor that couples to a pulse oximeter electronics and display unit. One of the two LEDs' primary wavelength is selected at a point in the electromagnetic spectrum where the absorption of oxyhemoglobin (HbO2) differs from the absorption of reduced hemoglobin (Hb). The second of the two LEDs' wavelength is selected at a different point in the spectrum where the absorption of Hb and HbO2 differs from those at the first wavelength. Commercial pulse oximeters typically utilize one wavelength in the near red part of the visible spectrum near 660 nanometers (nm) and one in the near infrared (IR) part of the spectrum in the range of 880-940 nm.


Oxygen saturation can be estimated using various techniques. In one common technique, first and second photo-current signals generated by the photo-detector from red and infrared light are conditioned and processed to determine AC and DC signal components and a modulation ratio of the red to infrared signals. This modulation ratio has been observed to correlate well to arterial oxygen saturation. Pulse oximeters and sensors are empirically calibrated by measuring the modulation ratio over a range of in vivo measured arterial oxygen saturations (SaO2) on a set of patients, healthy volunteers, or animals. The observed correlation is used in an inverse manner to estimate blood oxygen saturation (SpO2) based on the measured value of modulation ratios. The estimation of oxygen saturation using modulation ratio is described in U.S. Pat. No. 5,853,364, entitled “METHOD AND APPARATUS FOR ESTIMATING PHYSIOLOGICAL PARAMETERS USING MODEL-BASED ADAPTIVE FILTERING”, issued Dec. 29, 1998, and U.S. Pat. No. 4,911,167, entitled “METHOD AND APPARATUS FOR DETECTING OPTICAL PULSES”, issued Mar. 27, 1990. The relationship between oxygen saturation and modulation ratio is further described in U.S. Pat. No. 5,645,059, entitled “MEDICAL SENSOR WITH MODULATED ENCODING SCHEME,” issued Jul. 8, 1997. All three patents are assigned to the assignee of the present invention and incorporated herein by reference.


The accuracy of the estimates of the blood flow characteristics depends on a number of factors. For example, the light absorption characteristics typically vary from patient to patient depending on their physiology. Moreover, the absorption characteristics vary depending on the location (e.g., the foot, finger, ear, and so on) where the sensor is applied. Further, the light absorption characteristics vary depending on the design or model of the sensor. Also, the light absorption characteristics of any single sensor design vary from sensor to sensor (e.g., due to different characteristics of the light sources or photo-detector, or both). The clinician applying the sensor correctly or incorrectly may also have a large impact in the results, for example, by loosely or firmly applying the sensor or by applying the sensor to a body part which is inappropriate for the particular sensor design being used.


Some oximeters “qualify” measurements before displaying them on the monitor. One conventional technique processes (i.e., filters) the measured plethysmographic waveform and performs tests to detect and reject measurements perceived corrupted and inaccurate. Since oximeters are typically designed to be used with a wide variety of sensors having widely differing performance characteristics, the monitor signal “qualification” algorithms are necessarily crude, and often result in only superficial indications of signal quality, signal reliability, and ultimately a confidence level in a patient physiological characteristic estimated or calculated from the signal. In many instances, the monitor simply discards data associated with low quality signals, but otherwise gives no indication to a healthcare giver as to whether any physiological characteristic displayed on a monitor is highly reliable or not. Hence, the signal quality measurements obtained from such crude algorithms are relatively poor and convey little useful information to a caregiver.


SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a patient monitor and sensor which includes means for accurately detecting a quality of a signal detected by the sensor.


Another object of the invention is to provide a monitor and sensor which includes means for accurately determining a quality of a physical characteristic estimated from a signal obtained by a sensor.


A further object of the invention is to provide a monitor and sensor which includes means for detecting a transition between a signal regime considered normal for the sensor in its usual application, and a signal regime considered to be abnormal.


These and others objects of the invention are achieved by the use of a set of one or more signal specification boundaries. Each boundary defines a region of a signal quality diagram and corresponds to a different level of quality in the detected signals and accuracy or confidence level of physiological characteristic estimated from the detected signals. Boundaries can also be defined for and associated with different sensor types and monitor types. The boundaries are typically stored in a memory and accessed when required.


An embodiment of the invention provides a sensor for sensing at least one physiological characteristic of a patient. The sensor is connectable to a monitor that estimates a physiological condition from signals detected by the sensor. The sensor includes a detector for detecting the signals from the patient which are indicative of the physiological characteristic. The sensor is associated with a memory configured to store data that defines at least one sensor signal specification boundary for the detected signals. The boundary is indicative of a quality of the signals and an accuracy of the physiological characteristic estimated from the signals by the monitor. The sensor further includes means for providing access to the memory to allow transmission of the data that defines the at least one sensor boundary to the monitor.


In an embodiment, the boundary is indicative of a transition between a signal regime considered normal for the sensor in its usual application, and a signal regime considered to be abnormal. The normal regime can be one in which the sensor is likely to be properly applied to the patient and the abnormal regime can be one in which the sensor may have partially or entirely come off the patient.


Another embodiment of the invention provides a monitor for providing an indication of an accuracy of an estimated physiological condition of a patient. The monitor is connectable to a sensor that detects signals indicative of at least one physiological characteristic of the patient. The monitor includes at least one receiving circuit and at least one processing circuit. The receiving circuit is configured to receive the signals indicative of the at least one physiological characteristic and data defining at least one sensor signal specification boundary for the detected signals. The processing circuit is configured to estimate the physiological condition of the patient based on the received signals, compare the received signals against the at least one sensor boundary, and generate the indication of the accuracy of the estimated physiological condition. The monitor further includes means for providing the indication of the accuracy of the estimated physiological condition to a user of the monitor.


Yet another embodiment of the invention provides a pulse oximetry system that includes the sensor described above and a pulse oximetry monitor. The monitor has means to determine whether the signals are within a normal regime or an abnormal regime. The system further includes means for informing a user of the system as to whether the signal is normal or abnormal.


The foregoing, together with other aspects of this invention, will become more apparent when referring to the following specification, claims, and accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a simplified block diagram of an embodiment of a pulse oximeter system;



FIG. 2A shows a diagram of a specific embodiment of a sensor;



FIGS. 2B and 2C show diagrams of specific embodiments in which a memory is located within the sensor plug and within the sensor cable, respectively;



FIG. 2D shows a diagram of a specific embodiment of a monitor;



FIG. 3 shows a diagram of a simplified optical waveform detected by the sensor;



FIG. 4 shows a signal quality diagram that includes data of the measured DC and AC components;



FIG. 5 shows a signal quality diagram having defined regions corresponding to different confidence levels in the saturation estimate;



FIG. 6 shows a signal quality diagram having defined display and non-display regions (similar to those of FIG. 5) and transition zones;



FIG. 7 shows a flow diagram of an embodiment of the measurement posting process of the invention;



FIG. 8 shows a signal quality diagram with data collected from a patient population; and



FIG. 9 shows a signal quality diagram that includes ambiguity contours plotted over a portion of the display region.





DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The invention is applicable to measurement (or estimation) of oxygen saturation of hemoglobin in arterial blood and patient heart rate. The invention will be described in detail with respect to an embodiment for pulse oximetry, but it needs to be realized that the invention has applicability to alternate patient monitoring characteristics, such as ECG, blood pressure, temperature, etc., and is not to be limited to only for use with oximetry or pulse oximetry.



FIG. 1 shows a simplified block diagram of an embodiment of a pulse oximeter system 100. System 100 includes a pulse oximeter (or monitor) 110 that couples via an electrical cable 128 to a sensor 130 that is applied to a patient 132. Sensor 130 includes a sensor cable 129 and a connector plug 120. The sensor further has first and second light sources (e.g., LEDs) and a photo-detector along with suitable components to couple these electro-optical components to the electrical cable 128.


As noted above, oxygen saturation can be estimated using various techniques. In one common technique, the optical signals are received by the photo-detector, and conditioned and processed by the oximeter to generate AC and DC components. These components are then used to compute a modulation ratio of the red to infrared signals. The computed modulation ratio is then indexed against a table to retrieve a saturation estimate corresponding to that modulation ratio.



FIG. 2A shows a diagram of a specific embodiment of sensor 130. Sensor 130 includes two or more LEDs 230 and a photodetector 240. Sensor 130 may optionally include a memory 236a and an interface 238. LEDs 230 receive drive signals that (i.e., alternately) activate the LEDs. When activated, the light from LEDs 230 passes into a patient's tissues 234. After being transmitted through or reflected from the tissues, the light is received by photo-detector 240. Photo-detector 240 converts the received light into a photocurrent signal, which is then provided to the subsequent signal-processing unit.


The sensor memory stores data representative of at least one sensor signal specification boundary and provides the sensor boundary when requested. Interface circuit 238 provides signal conditioning, and can also provide other functions. Through interface circuit 238, data is transferred to and from the sensor memory. Memory 236a and interface circuit 238 can be integrated within one integrated circuit for reduced size and cost.


The memory associated with the sensor can be physically located in a variety of places. First, it can be located on the body of the sensor, in a vicinity of the photodetector, LEDs, or other sensor components. Or, the memory can be in the sensor cable 129 or the connector plug 120, or in an adapter module that connects to a front of an oximeter, to an oximeter cable, or to a sensor plug or cable.



FIG. 2B shows a diagram of a specific embodiment in which a memory 236b is located within the connector plug 120. Memory 236b couples to and interfaces with external circuitry through some or all signal lines provided to the sensor plug.



FIG. 2C shows a diagram of a specific embodiment in which a memory 236c is located within the sensor cable 129. Again, memory 236c couples to and interfaces with external circuitry through a set of signal lines.


The memory 236 can be implemented as a random access memory (RAM), a FLASH memory, a programmable read only memory (PROM), an erasable PROM (EPROM), an electrically erasable PROM (EEPROM), a write once memory, or other memory technologies capable of write and read operations. In a specific embodiment, to preserve the data stored in the memory and prevent accidental erasure, the sensor memory can be written only once. This memory characteristic also prevents erasure of the data during sensor operation. A specific example of a memory device that can be written only once is a 2-wire EPROM device available from Dallas Semiconductor Corp.



FIG. 2D shows a diagram of a specific embodiment of monitor 110. A receiving circuit 250 couples to the sensor and the memory associated with the sensor for receiving signals detected by the sensor and data from the sensor memory. The receiving circuit 250 couples to a processing circuit 252 that processes the received signals to generate an estimate of a physiological characteristic. The processing circuit 252 can further generate an indication of the quality of the received signal and an indication of the accuracy of the estimated physiological characteristic. The estimated physiological characteristic and associated indications are provided to a display unit 254 for display to a user of the monitor.



FIG. 3 shows a diagram of a simplified optical waveform 300 detected by a sensor (e.g., sensor 130). Optical waveform 300 in FIG. 3 can represent the detected optical signal for either the red or infrared LED. As shown in FIG. 3, optical waveform 300 includes a periodic pattern that generally corresponds to a patient's heartbeat. For arrhythmia patient, the waveform may be aperiodic. Waveform 300 includes a series of peaks having a maximum value (Max) and a series of valleys having a minimum value (Min). The following quantities are defined:















AC
=

Max
-
Min


;





Eq
.





(
1
)













DC
=


(

Max
-
Min

)

2


;





Eq
.





(
2
)














Modulation





percentage






(

Mod





%

)


=

100
·

(

AC
DC

)



;
and





Eq
.





(
3
)








nAv






(

nanoAmperes





virtual

)


=


DC

Instrument





gain


·


50





mA


actual





LED





drive





current





in





mA







Eq
.





(
4
)









where Instrument gain is a gain value that is specific to the combination of the pulse oximeter and a particular sensor that is used during the detection of the pulses in waveform 300. Nanoamperes virtual “normalizes” the signal to a 50 mA LED drive. Many oximeters contain servo systems which adjust LED drive intensity to be optimal for a particular set of monitoring conditions. By normalizing signal levels to a standard assumed LED drive level, it is possible to derive a measure of signal strength which is dependent primarily on the sensor and patient, and not on particular drive level which the instrument has selected.


The modulation ratio of the red to infrared signals, sometimes referred to as the “ratio of ratios” (Ratrat), can be approximated as:










Ratrat



(

AC_Red
DC_Red

)


(

AC_IR
DC_IR

)



;




Eq
.





(
5
)









where AC_Red and DC_Red are the respective AC and DC components of the red LED, and AC_IR and DC_IR are the respective AC and DC components of the infrared LED. Oxygenation derived from Ratrat using equation (5) is sufficiently accurate for many applications when the condition (AC<<DC) is satisfied. Particularly, the approximation error is small when both AC terms in equation (5) are less than ten percent of the related DC terms (i.e., both red and infrared modulations are less than 10%).


As stated above, oxygen saturation is related to Ratrat. The relationship between Ratrat and oxygen saturation is typically plotted as a curve (i.e., saturation versus Ratrat) and stored as a table in the memory within the oximeter. Subsequently, a calculated Ratrat is used to index the table to retrieve an entry in the table for the oxygen saturation estimate corresponding to that Ratrat. The estimation of oxygen saturation using Ratrat is further described in U.S. Pat. Nos. 4,911,167, 5,645,059, and 5,853,364.


Generally, the Red terms are measured in the red part of the optical spectrum using the red LED, and the IR terms are measured in the infrared part of the optical spectrum using the infrared LED. The AC terms are generated by the blood pressure pulse and are somewhat related to “perfusion.” The DC terms are (inversely) related to the “opacity” (or darkness) of the patient being monitored and are somewhat related to “translucence.” Generally, the four terms in equation (5) are independent of each other. However, empirical studies suggest that the two DC terms are somewhat correlated (i.e., not wildly divergent), and patients who are “opaque” tend to be opaque in both the red and infrared parts of the spectrum.


It has been determined that the magnitudes of the DC and AC components influence the accuracy of the saturation estimates and these magnitudes depend on the sensor design being used, the specifications of components used in the sensor, and how the sensor has been applied to the patient. The invention advantageously utilizes this knowledge to provide an oximeter system capable of providing indications of the accuracy and reliability of the saturation estimates. Additional features are provided by the invention based on the analysis of the measured DC and AC components, as described below.



FIG. 4 shows a signal quality diagram that includes data of the measured DC and AC components. The vertical axis of the signal quality diagram corresponds to the modulation percentage (Mod %) which is calculated as shown in equation (3) for each of the red and infrared signals. The horizontal axis corresponds to the DC component and is in units of virtual nano Amperes (nAv) and is given by equation (4). As shown in FIG. 4, both vertical and horizontal axes are plotted on a logarithmic scale.


As noted above, the detected optical waveform includes an AC component and a DC component. The DC component is plotted on the horizontal axis and the ratio of AC to DC is expressed as a percentage (e.g., Mod %) and plotted on the vertical axis. Since two different optical signals are measured (i.e., for the red and infrared wavelengths), two points are generated and plotted on the signal quality diagram to uniquely identify the AC and DC components of both the red and infrared optical signals. In FIG. 4, the data points corresponding to the red wavelength are identified by a square and the data points corresponding to the infrared wavelength are identified by a diamond.



FIG. 4 shows the relative positions of two data points associated with two patients on the signal quality diagram. For a (stable) patient and over a short duration (i.e., of few pulses), all four Ratrat constituents (Red AC, DC; and Infrared AC, DC) remain approximately constant. The data points for patient A indicate a patient with low light levels (i.e., low DC component values) and low modulation (i.e., low Mod %). These data points could correspond to data from, for example, a chubby, dark-skinned neonate who has poor perfusion, or a reflectance sensor applied to a poorly perfused site (i.e., on the foot). Conversely, the data points for patient B indicate a very translucent patient with good perfusion that results in high light levels and high modulation.


The pair of data points for each patient, one data point for red wavelength and one for infrared wavelength, defines the patient's current (Ratrat) conditions. Equivalently, the pair of data points describes the oximeter's “operating point,” when the oximeter is monitoring that patient. For a particular patient, the pair of data points can be used to estimate the patient's saturation using equation (5) and a table for saturation versus Ratrat. For example, the Ratrat for patient A is approximately 0.12/0.25 or 0.48. For a typical oximeter, this Ratrat corresponds to a saturation of approximately 100%. The Ratrat for patient B is approximately 6/7 or 0.86, which corresponds to a saturation of approximately 85%.


In an embodiment, for each particular combination of oximeter model and sensor model, data points are collected for numerous “patients.” These data points can be collected under a controlled test environment where true oxygen saturation is known, and an accuracy of the saturation estimated from the red and infrared signals can be determined. Based on the collected data, the diagram can be partitioned into regions corresponding to different levels of quality and accuracy in the saturation estimate. The regions also indicate a quality of the detected signals. Each region is defined by a signal boundary.


The signal boundaries are dependent on many factors such as the monitor type, sensor type, specifications of components in the sensor (e.g., wavelength, LED characteristics), and other factors. In an embodiment, sensor specific boundaries are stored in the sensor memory or other locations associated with the sensor.



FIG. 5 shows a sensor signal quality diagram having defined regions corresponding to different confidence levels in the saturation estimate. A display region 510 defines a portion of the signal quality diagram associated with saturation estimates that satisfy a predetermined quality and accuracy level and merit posting (or displaying) on the monitor. Display region 510 includes the set of “patient conditions” resulting in sufficiently accurate saturation estimates for a particular application. Accordingly, when the data points fall within display region 510, the saturation estimate (which is derived from the data points) is posted. Conversely, when the data points fall outside display region 510 into a non-display region 512, the saturation estimate corresponding to these data points is not posted on the oximeter display. Non-display region 512 lies outside, and generally surrounds, display region 510.


The DC signal corresponding to the red LED is generally “weaker” than the detected signal from the infrared LED. Since this characteristic is known a priori, the oximeter can be designed to account for this difference. In one implementation, the red LED is associated with a first display region and the infrared LED is associated with a second display region. For example, referring to FIG. 5, the red display region is defined by lines 520, 522, 526, and 528, and the infrared display region is defined by lines 520, 524, 526, and 530. Since the red signals are generally weaker than the infrared signal, the boundary of the red display region tends to be closer to the lower left corner of the signal quality diagram.


The display region may be dependent on numerous operating conditions. For example, ambient light typically adds to the detected optical signals (i.e., increases the DC components) and thus may alter the display region. In this case, the display region could be adjusted to account for the perturbation of the signal caused by the (or distortion introduced by) ambient light.



FIG. 6 shows a signal quality diagram having defined display and non-display regions (similar to those of FIG. 5) and a transition zone 614. Transition zone 614 includes regions of the diagram that lie between the display and non-display regions. The transition zone represents regions associated with a different (e.g., intermediate) quality and accuracy level than those of the display and non-display regions. A different set of criteria can be used when evaluating data points that fall within the transition zone, as described below.


The regions shown in FIGS. 5 and 6 are only representatives of a particular oximeter/sensor combination and for a particular set of operating conditions. Each oximeter (or each oximeter model or type) is typically associated with its own set of display and non-display regions, which may differ from those shown in FIGS. 5 and 6. Some oximeters may even have poorly defined non-display regions, where the boundaries vary depending on a set of factors. These factors include the signal-to-noise ratio (SNR) of the oximeter, the amount of ambient light, the wavelength of the sensor LEDs, and so on.


In an embodiment, the oximeter operates in accordance with the following set of rules:

    • If both data points (i.e., for the red and infrared signals) fall within their respective display regions, the oximeter posts the result (e.g., the saturation estimate, and heart rate).
    • If either data point falls within its non-display region, the oximeter does not post the result.
    • In all other cases, the oximeter may or may not post the result. These cases include instances in which one of the signals falls in the transition zone and neither signal falls in the non-display region.


Thus, the saturation estimate is posted if the modulation percentage (Mod %) and the light level (DC components) for both the red and infrared wavelengths fall within the bounded areas of their respective display regions. In an embodiment, if the red signal falls within the red non-display region or if the infrared signal falls within the infrared non-display region, or both, then the oximeter does not post the saturation estimate. It can be noted that other sets of rules can also be applied. For example, in another embodiment, the result is posted if one of the data points falls within its display region and the other data point falls within the transition zone. In yet another embodiment, the oximeter posts the saturation estimate and also indicates either the regions in which the data points fall or a confidence level based on the regions in which the data points fall.


For clarity, FIG. 5 shows only display and non-display regions. These regions correspond to data points that are to be displayed and not displayed. However, additional regions can be defined within the signal quality diagram, with the additional regions corresponding to different confidence levels in the saturation estimate. Generally, the confidence level is high for data points that fall near the center of the diagram and decreases as the data points move away from the center. For the embodiment having multiple confidence levels, the oximeter can display the saturation estimate along with the confidence level.


For example, an “inactive” region can be defined and used to indicate when a sensor is not applied to a patient. The inactive region may be used to detect and notify when the sensor has been removed (i.e., fallen off) the patient. The inactive region lies outside the display and transition regions, correlates to measurements from sensors that are not attached to patients, and typically comprises a portion of the non-display region. This region can be defined through simulation or through empirical measurements. The oximeter computes the data points in the manner described above. If the data points fall inside the inactive region, the oximeter displays an indication that the sensor has been removed from the patient.



FIG. 7 shows a flow diagram of an embodiment of the measurement display process of the invention. At a step 712, one or more signals indicative of a physiological parameter are detected. For an oximeter used to measure oxygen saturation, this detecting step may include, for example, receiving optical signals from two LEDs and conditioning these signals. At a step 714, the detected signal(s) are processed to generate intermediate data points. For oxygen saturation, this processing step may include filtering the data samples to generate DC and AC components, and using these components to generate the modulation percentage (Mod %). The intermediate data points would include filtered values for the DC component and computed values of the modulation percentage. The intermediate data points are then compared against a signal quality diagram (step 716). This diagram is generated previously, in a manner described above.


At step 718, it is determined whether the intermediate data points fall within the display region. If the answer is yes, the physiological parameter is estimated based on the detected and processed signal(s). For example, the oxygen saturation can be estimated from the computed Mod % for the two LEDs using equation (5). At step 722, the estimated physiological parameter is displayed, and the process terminates.


If it is determined at step 718 that the data points do not fall within the display region, a determination is made whether the data points fall within the inactive region (step 724). If the answer is yes, an error message is displayed at step 726. This error message may inform the clinician of the error data points (e.g., “ERROR MEASUREMENT”), provide a suggestion (e.g., “TRY ANOTHER SITE”), and so on. The process then terminates. In some embodiments of the invention, step 724 is not performed.


If it is determined at step 724 that the data points do not fall within the inactive region, a determination is made whether the data points fall within the non-display region, at a step 730. If the answer is yes, the measurement is not displayed. An error message may be displayed to inform the clinician. This error message may inform the clinician of the invalid data points (e.g., “INVALID MEASUREMENT” or “WEAK SIGNAL”), provide a suggestion (e.g., “TRY ANOTHER SITE”), and so on. The process then terminates.


If it is determined at step 730 that the data points do not fall within the non-display region, a determination is made whether the data points fall within the transition region, at step 736. If the answer is yes, a warning message may be displayed to warn the clinician. This warning message may indicate that the data points are of questionable accuracy (e.g., “INACCURATE MEASUREMENT” or “WEAK SIGNAL”), provide a suggestion (e.g., “TRY ANOTHER SITE”), and so on. The physiological parameter may also be computed and displayed along with the warning message. The process then terminates. In some embodiments of the invention, step 736 is not performed.



FIG. 8 shows a signal quality diagram with data collected from a patient population. The patient data can be used to define the display and non-display regions, to characterize the patient population's mean modulation percentage and mean nAv for both red and infrared wavelengths, to characterize measurement ambiguity that is indicative of the instrument's accuracy, or a combination of the above. Ambiguity as used herein, which is an approximate indication of instrument error, is the sum of the mean error (bias) of an instrument and the stability of the readings obtained (wander). The stability of the readings obtained (wander) is the standard deviation of the instrument readings.


The ambiguity, or estimated error, for various combinations of modulation and DC component are then plotted on the signal quality diagram. The average saturation, saturation bias, saturation wander, and ambiguity can be computed using equal weighting (i.e., giving the same importance for each data point) or unequal weighting that accounts for population statistics (i.e., giving less importance to data points that occur more rarely). Signal specification boundaries can also be obtained for a particular patient sub-population (e.g., perinatal patients) to further improve accuracy in the measurement reporting when the instrument is used for that particular patient sub-population.



FIG. 9 shows a signal quality diagram that includes ambiguity contours plotted over a portion of the display region. Each contour line corresponds to a particular ambiguity, in saturation points. As an example, at an infrared operating point of 10 nAv and three percent modulation, the plots show an ambiguity of between 10 and 12 saturation points. The contour lines can be generated by collecting data points, grouping the data points that have similar infrared DC components, and selecting a representative ambiguity for those data points. The selected ambiguities for the groups of data points are plotted as a two-dimensional contour plot.


In an embodiment, the largest ambiguity in each group is selected as representative of the group and a contour plot of the worse case ambiguity is generated. This information is useful, for example, in an oximeter having a guaranteed limit on the saturation ambiguity, and only data points within the guaranteed limit are posted. Other variations of the contour plots shown in FIG. 9 are possible. For example, contour plots can be generated for: (1) the worst case ambiguity, (2) the average ambiguity, (3) the worst case or average absolute value of the bias, (4) the worst case or average value of the wander, and others. The average ambiguity contour plots are generated based on the average of the ambiguities obtained for each group, and are useful for indicating typical ambiguity that is likely to occur for that modulation and infrared DC component.


The contour plots on the signal quality diagram can also be adjusted for, or take into account, different pulse rates and abnormal heart rhythms such as arrhythmias, premature ventricular contractions, bigeminy, fibrillation, cardiac arrest, and other cardiac pathologies.


The invention provides advantages not available in conventional oximeters. For example, by detecting data points corresponding to saturation estimates having a low degree of confidence and discarding these estimates (or indicating the low degree of confidence), the invention provides an oximeter having improved diagnostic accuracy and reliability. This ensures that the results relied upon by the clinician meet a predetermined reliability criteria. The invention may also be used to detect and notify when the sensor has been removed (i.e., fallen off) the patient, as described above.


The oximeter of the invention can also be used to assist the clinician take more accurate measurements. This is a particularly useful application of the invention since it is known that some clinicians move the sensor to various parts of the patient in an attempt to obtain better readings. To assist the clinician, the oximeter can be programmed to display an indicator signal that indicates whether a selected site is good or poor for application of the sensor. This prompt may also be used to assist a less experienced clinician administer the saturation measurement.


The invention can be used for various physiological measurements. The application of the invention to pulse oximetry has been described as only one preferred embodiment. The invention can also be applied to other physiological measurements such as ECG, blood pressure, temperature, heart rate, and so on. Accordingly, the invention is not to be limited for use only with oximetry or pulse oximetry.


The foregoing description of the preferred embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without the use of further invention. For example, the invention can be applied to measurements of other physiological characteristics. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims
  • 1. A system for detecting at least one physiological characteristic of a patient, comprising: a sensor, comprising: a detector adapted to generate signals indicative of the at least one physiological characteristic; anda memory storing data defining at least one sensor specific boundary that is indicative of a transition between a signal regime considered to be normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal for the sensor in the sensor's usual application, wherein the at least one sensor specific boundary is indicative of a quality of the signals generated by the sensor and an accuracy of an estimated physiological condition of the patient; anda monitor, comprising: a first receiving circuit configured to receive the signals indicative of the at least one physiological characteristic from the sensor;a first processing circuit configured to provide the estimated physiological condition of the patient based on the signals;a second receiving circuit configured to receive the data defining the at least one sensor specific boundary for the signals from the sensor; anda second processing circuit configured to compare the signals against the sensor specific boundary and to generate an indication of the accuracy of the estimated physiological condition, wherein the second processing circuit is further configured to determine whether the signals are within the normal regime or the abnormal regime.
  • 2. The system of claim 1, wherein the sensor specific boundary is characteristic of a model of the sensor or of individual components used in the sensor.
  • 3. The system of claim 1, wherein the memory is physically located on one of a sensor body, sensor cable, sensor connecting plug, or a sensor adapter module.
  • 4. The system of claim 1, wherein the signals are based on light emissions scattered from the patient, the light emissions having first and second wavelengths, the light emissions each having an AC modulation component.
  • 5. The system of claim 1, wherein the detector is a photodetector.
  • 6. The system of claim 1, wherein the signals are indicative of an arterial oxygen saturation of the patient.
  • 7. The system of claim 1, wherein the memory is adapted to be written to only once to prevent erasure of the data during sensor operation.
  • 8. A method of manufacturing a system, comprising: providing a sensor comprising a detector configured to generate signals that are indicative of a physiological characteristic of a patient;providing a memory coupled with the sensor, the memory storing data defining at least one sensor signal specification boundary for the signals, the at least one sensor signal specification boundary being indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal, wherein the at least one sensor signal specification boundary is indicative of a quality of the signals generated by the sensor and an accuracy of an estimated physiological condition of the patient, andproviding a monitor configured to receive the signals indicative of the physiological characteristic from the sensor, to provide the estimated physiological condition of the patient based on the signals, to receive the data defining the at least one sensor signal specification boundary for the signals from the sensor, to compare the signals against the at least one sensor signal specification boundary, and to generate an indication of the accuracy of the estimated physiological condition and to determine whether the signals are within the normal regime or the abnormal regime based on the comparison of the signals to the at least one sensor signal specification boundary.
  • 9. The method of claim 8, wherein the at least one sensor signal specification boundary is characteristic of a model of the sensor or of individual components used in making the sensor.
  • 10. A method of manufacturing a system, comprising: providing a sensor comprising a detector configured to generate signals that are indicative of a physiological characteristic of a patient;providing a memory coupled to the sensor, the memory storing data defining at least one sensor signal specification boundary for the signals, the at least one sensor signal specification boundary being indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal, wherein the at least one signal specification boundary is characteristic of a model of the sensor or of individual components used in the sensor; andproviding a monitor configured to receive the signals from the sensor, to receive the data defining the at least one sensor signal specification boundary for the signals from the sensor, to determine an estimated physiological condition of the patient based on the signals, to compare the received signals with the at least one sensor signal specification boundary, and to generate an indication of the accuracy of the estimated physiological condition and to determine whether the signals are within a normal regime for the sensor in the sensor's usual application or an abnormal regime for the sensor in the sensor's usual application based on the comparison of the received signals to at least one sensor signal specification boundary.
  • 11. A method of operating a system for detecting at least one physiological characteristic, comprising: generating, with a sensor, signals from a patient that are indicative of the physiological characteristic; andaccessing a memory coupled to the sensor to facilitate transmission of data defining at least one sensor signal specification boundary, the sensor signal specification boundary being indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal, wherein the at least one sensor specific boundary is indicative of a quality of the signals generated by the sensor and an accuracy of an estimated physiological condition of the patient;transmitting from the sensor to a monitor the signals indicative of at least one physiological characteristic;determining the estimated physiological condition of the patient via the monitor based on the signals;transmitting data defining the at least one sensor signal specification boundary for the signals from the sensor to the monitor;comparing via the monitor the signals against the sensor signal specification boundary;generating via the monitor an indication of the accuracy of the estimated physiological condition; anddetermining via the monitor whether the signals are within the normal regime or the abnormal regime.
  • 12. The method of claim 11, wherein the sensor signal specification boundary is characteristic of a model of the sensor or of individual components used in the sensor.
  • 13. A monitor for providing an indication of an accuracy of an estimated physiological condition of a patient, the monitor being coupleable to a sensor that generates signals indicative of at least one physiological characteristic of the patient, the monitor comprising: a first receiving circuit configured to receive the signals indicative of the at least one physiological characteristic from the sensor;a first processing circuit configured to provide an estimated physiological condition of the patient based on the signals;a second receiving circuit configured to receive data defining at least one sensor signal specification boundary for the signals from the sensor, the sensor signal specification boundary being indicative of a quality of the signals generated by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the sensor signal specification boundary is indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal; anda second processing circuit configured to compare the signals against the sensor signal specification boundary and to generate an indication of the accuracy of the estimated physiological condition, wherein the second processing circuit is further configured to determine whether the signals are within the normal regime or the abnormal regime.
  • 14. The monitor of claim 13, comprising a display device configured to display the estimated physiological characteristic.
  • 15. The monitor of claim 13, wherein the normal regime is one in which the sensor is likely to be properly coupled to the patient and the abnormal regime is one in which the sensor is likely to have partially or fully decoupled from the patient.
  • 16. The monitor of claim 13, wherein the second processing circuit is configured to compute an indication of whether the sensor is likely to be coupled to the patient or has partially or entirely decoupled from the patient.
  • 17. The monitor of claim 13, wherein the monitor is a pulse oximetry monitor comprising: a processor configured to determine whether the signals are within the normal regime; anda display configured to inform a user whether the signals are normal or abnormal.
  • 18. The monitor of claim 13 wherein the monitor is a pulse oximetry monitor comprising: a processor configured to determine whether the signals are within the normal regime or the abnormal regime; andan alarm that is triggered when the signals move from the normal regime to the abnormal regime.
  • 19. A method of operating a monitor for providing an indication of an accuracy of an estimated physiological condition of a patient, comprising: receiving from a sensor signals indicative of at least one physiological characteristic;determining the estimated physiological condition of the patient based on the signals;receiving data defining at least one sensor signal specification boundary for the signals, the sensor signal specification boundary being indicative of a quality of the signals detected by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the at least one sensor signal specification boundary is indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal;comparing the signals against the sensor signal specification boundary;generating an indication of the accuracy of the estimated physiological condition; anddetermining whether the signals are within the normal regime or the abnormal regime.
  • 20. The method of claim 19, further comprising: displaying the estimated physiological characteristic; andmonitoring boundaries stored in the monitor.
  • 21. A method of manufacturing a monitor for providing an indication of an accuracy of an estimated physiological condition of a patient, the monitor being coupleable to a sensor that generates signals indicative of at least one physiological characteristic of the patient, comprising: providing a processing circuit configured to determine an estimated physiological condition of the patient based on the signals, compare the signals with at least one sensor signal specification boundary, generate an indication of the accuracy of the estimated physiological condition, and determine whether the signals are within a normal regime for the sensor in the sensor's usual application or an abnormal regime for the sensor in the sensor's usual application; andproviding a receiving circuit configured to receive the signals from the sensor and receive data defining the sensor signal specification boundary for the signals from the sensor, the sensor signal specification boundary being indicative of a quality of the signals generated by the sensor and an accuracy of the estimated physiological characteristic, wherein the sensor signal specification boundary is indicative of a transition between the normal regime and the abnormal regime.
  • 22. A system, for detecting at least one physiological characteristic of a patient, comprising: a sensor, comprising: a detector configured to generate signals that are indicative of the physiological characteristic;a memory coupled to the sensor, the memory storing data defining at least one sensor signal specification boundary for the signals, the sensor signal specification boundary being indicative of a transition between a signal regime considered normal for the sensor in the sensor's usual application and a signal regime considered to be abnormal and being indicative of a quality of the signals generated by the sensor; andan integrated circuit providing access to the memory to facilitate transmission of the data defining the at least one sensor signal specification boundary; anda monitor, comprising: a processing circuit configured to determine an estimated physiological condition of the patient based on the signals, compare the signals with the at least one sensor signal specification boundary, generate an indication of the accuracy of the estimated physiological condition, and determine whether the signals are within the normal regime or the abnormal regime; anda receiving circuit configured to receive the signals indicative of the at least one physiological characteristic and to receive data defining the at least one sensor signal specification boundary, the sensor signal specification boundary being indicative of an accuracy of the estimated physiological characteristic.
  • 23. A system for detecting at least one physiological characteristic of a patient, comprising: a detector of a sensor adapted to generate signals indicative of the at least one physiological characteristic; anda memory coupled to or integral with the sensor storing data defining at least one specific boundary characteristic of a model of the sensor, the at least one specific boundary characteristic being indicative of a quality of the signals generated by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the at least one specific boundary characteristic is indicative of a transition between a normal signal regime considered to be of sufficient quality and accuracy for the sensor when applied to a patient and an abnormal signal regime considered to be of insufficient quality and accuracy for the sensor when applied to the patient, the memory adapted to allow transmission of the boundary to a monitor to enable the monitor to display the estimated physiological characteristic when the signals fall within the normal signal regime and to display an indication of when the signals fall within the abnormal signal regime; andthe monitor, comprising: a first receiving circuit configured to receive the signals indicative of the at least one physiological characteristic from the sensor;a first processing circuit configured to provide the estimated physiological characteristic of the patient based on the signals;a second receiving circuit configured to receive data defining at least one sensor signal specification boundary for the signals from the memory; anda second processing circuit configured to compare the signals against the sensor signal specification boundary and to generate an indication of the accuracy of the estimated physiological characteristic, wherein the second processing circuit is further configured to determine whether the signals are within the normal regime or the abnormal regime.
  • 24. The system of claim 23, wherein the normal signal regime is one in which the sensor is likely to be properly coupled to the patient and the abnormal signal regime is one in which the sensor is likely to have partially or fully decoupled from the patient.
  • 25. The system of claim 23, wherein the at least one specific boundary is characteristic of individual components used in the sensor.
  • 26. The system of claim 23, wherein the memory is physically located on one of a sensor body, sensor cable, sensor connecting plug, or a sensor adapter module.
  • 27. The system of claim 23, wherein the signals are based on light scattered from the patient, the light having first and second wavelengths, and the first and second wavelengths each having an AC modulation component and a DC component.
  • 28. The system of claim 23, wherein the detector is a photodetector.
  • 29. The system of claim 23, wherein the signals are indicative of an arterial oxygen saturation.
  • 30. The system of claim 23, wherein the memory is adapted to be written to only once to prevent erasure of the data during sensor operation.
  • 31. A method of operating a system for detecting at least one physiological characteristic, comprising: generating, with a sensor, signals from a patient that are indicative of the physiological characteristic;accessing a memory coupled to the sensor to facilitate transmission of data defining at least one specific boundary characteristic of a model of the sensor, the at least one specific boundary characteristic being indicative of a quality of the signals generated by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the at least one specific boundary characteristic is indicative of a transition between a normal signal regime considered to be of sufficient quality and accuracy for the sensor when applied to a patient and an abnormal signal regime considered to be of insufficient quality and accuracy for the sensor when applied to the patient;transmitting from the sensor to the monitor the signals indicative of at least one physiological characteristic;determining the estimated physiological characteristic of the patient via the monitor based on the signals;transmitting data defining the at least one specific boundary characteristic for the signals;comparing via the monitor the signals against the at least one specific boundary characteristic;generating via the monitor an indication of the accuracy of the estimated physiological characteristic; anddetermining via the monitor whether the signals are within the normal signal regime or the abnormal signal regime.
  • 32. The method of claim 31, wherein the normal signal regime is one in which the sensor is likely to be properly coupled to the patient and the abnormal signal regime is one in which the sensor is likely to have partially or fully decoupled from the patient.
  • 33. A monitor for providing an indication of an accuracy of an estimated physiological condition of a patient, the monitor being coupleable to a sensor that generates signals indicative of at least one physiological characteristic of the patient, the monitor comprising: a first receiving circuit configured to receive the signals indicative of the at least one physiological characteristic from the sensor;a first processing circuit configured to provide an estimated physiological condition of the patient based on the signals;a second receiving circuit configured to receive data defining at least one sensor signal specification boundary for the signals from the sensor, the sensor signal specification boundary being indicative of a quality of the signals generated by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the sensor signal specification boundary is indicative of a transition between a normal signal regime considered to be of sufficient quality and accuracy for the sensor when applied to a patient and an abnormal signal regime considered to be of insufficient quality and accuracy for the sensor when applied to the patient, and the at least one sensor signal specification boundary is characteristic of a model of the sensor or individual components of the sensor; anda second processing circuit configured to compare the signals against the sensor signal specification boundary and to generate an indication of the accuracy of the estimated physiological condition, wherein the second processing circuit is further configured to determine whether the signals are within the normal regime or the abnormal regime.
  • 34. The monitor of claim 33, comprising a display device configured to display the estimated physiological characteristic.
  • 35. The monitor of claim 33, wherein the normal signal regime is one in which the sensor is likely be properly coupled to the patient and the abnormal signal regime is one in which the sensor is likely to have partially or fully decoupled from the patient.
  • 36. The monitor of claim 33, wherein the second processing circuit is configured to compute an indication of whether the sensor is likely to be coupled to the patient or has partially or entirely decoupled from the patient.
  • 37. The monitor of claim 33, wherein the monitor is a pulse oximetry monitor comprising: a processor configured to determine whether the signals are within the normal signal regime; anda display configured to inform a user whether the signals are normal or abnormal.
  • 38. The monitor of claim 33, wherein the monitor is a pulse oximetry monitor comprising: a processor configured to determine whether the signals are within the normal signal regime or the abnormal signal regime; andan alarm that is triggered when the signals move from the normal signal regime to the abnormal regime.
  • 39. A method of operating a monitor for providing an indication of an accuracy of an estimated physiological condition of a patient, comprising: receiving from a sensor signals indicative of at least one physiological characteristic;determining the estimated physiological condition of the patient based on the signals;receiving data defining at least one sensor signal specification boundary for the signals, the sensor signal specification boundary being indicative of a quality of the signals detected by the sensor and an accuracy of the estimated physiological characteristic estimated from the signals, wherein the at least one sensor signal specification boundary is indicative of a transition between a normal signal regime considered to be of sufficient quality and accuracy for the sensor when applied to a patient and an abnormal signal regime considered to be of insufficient quality and accuracy for the sensor when applied to the patient, and the at least one sensor signal specification boundary is characteristic of a model of the sensor or individual components of the sensor;comparing the signals against the sensor signal specification boundary;generating an indication of the accuracy of the estimated physiological condition; anddetermining whether the signals are within the normal signal regime or the abnormal signal regime.
  • 40. The method claim 39, further comprising: displaying the estimated physiological characteristic; andmonitoring boundaries stored in the monitor.
  • 41. The method of claim 39, further comprising: triggering an alarm when the signals move from the normal signal regime to the abnormal signal regime.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 10/712,895, filed Nov. 12, 2003 now U.S. Pat. No. 7,457,652, which is a continuation of U.S. application Ser. No. 09/545,170, filed Apr. 6, 2000, now U.S. Pat. No. 6,675,031, which claims the benefit of U.S. Provisional Application No. 60/129,170, filed on Apr. 14, 1999, the disclosures of which are hereby incorporated.

US Referenced Citations (931)
Number Name Date Kind
3638640 Shaw Feb 1972 A
3721813 Condon et al. Mar 1973 A
4586513 Hamaguri May 1986 A
4603700 Nichols et al. Aug 1986 A
4621643 New, Jr. et al. Nov 1986 A
4653498 New, Jr. et al. Mar 1987 A
4685464 Goldberger et al. Aug 1987 A
4694833 Hamaguri Sep 1987 A
4697593 Evans et al. Oct 1987 A
4700708 New, Jr. et al. Oct 1987 A
4714080 Edgar, Jr. et al. Dec 1987 A
4714341 Hamaguri et al. Dec 1987 A
4759369 Taylor Jul 1988 A
4770179 New, Jr. et al. Sep 1988 A
4773422 Isaacson et al. Sep 1988 A
4776339 Schreiber Oct 1988 A
4781195 Martin Nov 1988 A
4796636 Branstetter et al. Jan 1989 A
4800495 Smith Jan 1989 A
4800885 Johnson Jan 1989 A
4802486 Goodman et al. Feb 1989 A
4805623 Jöbsis Feb 1989 A
4807630 Malinouskas Feb 1989 A
4807631 Hersh et al. Feb 1989 A
4819646 Cheung et al. Apr 1989 A
4819752 Zelin Apr 1989 A
4824242 Frick et al. Apr 1989 A
4825872 Tan et al. May 1989 A
4825879 Tan et al. May 1989 A
4830014 Goodman et al. May 1989 A
4832484 Aoyagi et al. May 1989 A
4846183 Martin Jul 1989 A
4848901 Hood, Jr. Jul 1989 A
4854699 Edgar, Jr. Aug 1989 A
4858615 Meinema Aug 1989 A
4859056 Prosser et al. Aug 1989 A
4859057 Taylor et al. Aug 1989 A
4863265 Flower et al. Sep 1989 A
4865038 Rich et al. Sep 1989 A
4867557 Takatani et al. Sep 1989 A
4869253 Craig, Jr. et al. Sep 1989 A
4869254 Stone et al. Sep 1989 A
4880304 Jaeb et al. Nov 1989 A
4883055 Merrick Nov 1989 A
4883353 Hansman et al. Nov 1989 A
4890619 Hatschek Jan 1990 A
4892101 Cheung et al. Jan 1990 A
4901238 Suzuki et al. Feb 1990 A
4908762 Suzuki et al. Mar 1990 A
4911167 Corenman et al. Mar 1990 A
4913150 Cheung et al. Apr 1990 A
4926867 Kanda et al. May 1990 A
4927264 Shiga et al. May 1990 A
4928692 Goodman et al. May 1990 A
4934372 Corenman et al. Jun 1990 A
4936679 Mersch Jun 1990 A
4938218 Goodman et al. Jul 1990 A
4942877 Sakai et al. Jul 1990 A
4948248 Lehman Aug 1990 A
4955379 Hall Sep 1990 A
4960126 Conlon et al. Oct 1990 A
4964408 Hink et al. Oct 1990 A
4971062 Hasebe et al. Nov 1990 A
4972331 Chance Nov 1990 A
4974591 Awazu et al. Dec 1990 A
5007423 Branstetter et al. Apr 1991 A
5025791 Niwa Jun 1991 A
RE33643 Isaacson et al. Jul 1991 E
5028787 Rosenthal et al. Jul 1991 A
5040539 Schmitt et al. Aug 1991 A
5054488 Muz Oct 1991 A
5055671 Jones Oct 1991 A
5058588 Kaestle Oct 1991 A
5065749 Hasebe et al. Nov 1991 A
5066859 Karkar et al. Nov 1991 A
5069213 Polczynski Dec 1991 A
5078136 Stone et al. Jan 1992 A
5084327 Stengel Jan 1992 A
5088493 Giannini et al. Feb 1992 A
5090410 Saper et al. Feb 1992 A
5094239 Jaeb et al. Mar 1992 A
5094240 Muz Mar 1992 A
5099841 Heinonen et al. Mar 1992 A
5099842 Mannheimer et al. Mar 1992 A
H1039 Tripp et al. Apr 1992 H
5104623 Miller Apr 1992 A
5109849 Goodman et al. May 1992 A
5111817 Clark et al. May 1992 A
5113861 Rother May 1992 A
5119815 Chance Jun 1992 A
5122974 Chance Jun 1992 A
5125403 Culp Jun 1992 A
5127406 Yamaguchi Jul 1992 A
5131391 Sakai et al. Jul 1992 A
5140989 Lewis et al. Aug 1992 A
5152296 Simons Oct 1992 A
5154175 Gunther Oct 1992 A
5158082 Jones Oct 1992 A
5167230 Chance Dec 1992 A
5170786 Thomas et al. Dec 1992 A
5188108 Secker et al. Feb 1993 A
5190038 Polson et al. Mar 1993 A
5193542 Missanelli et al. Mar 1993 A
5193543 Yelderman Mar 1993 A
5203329 Takatani et al. Apr 1993 A
5209230 Swedlow et al. May 1993 A
5213099 Tripp et al. May 1993 A
5216598 Branstetter et al. Jun 1993 A
5217012 Young et al. Jun 1993 A
5217013 Lewis et al. Jun 1993 A
5218962 Mannheimer et al. Jun 1993 A
5224478 Sakai et al. Jul 1993 A
5226417 Swedlow et al. Jul 1993 A
5228440 Chung et al. Jul 1993 A
5237994 Goldberger Aug 1993 A
5239185 Ito et al. Aug 1993 A
5246002 Prosser Sep 1993 A
5246003 DeLonzor Sep 1993 A
5247931 Norwood Sep 1993 A
5247932 Chung et al. Sep 1993 A
5249576 Goldberger et al. Oct 1993 A
5253645 Freidman et al. Oct 1993 A
5253646 Delpy et al. Oct 1993 A
5259381 Cheung et al. Nov 1993 A
5259761 Schnettler et al. Nov 1993 A
5263244 Centa et al. Nov 1993 A
5267562 Ukawa et al. Dec 1993 A
5267563 Swedlow et al. Dec 1993 A
5273036 Kronberg et al. Dec 1993 A
5275159 Griebel Jan 1994 A
5279295 Martens et al. Jan 1994 A
5285783 Secker Feb 1994 A
5285784 Seeker Feb 1994 A
5287853 Vester et al. Feb 1994 A
5291884 Heinemann et al. Mar 1994 A
5297548 Pologe Mar 1994 A
5299120 Kaestle Mar 1994 A
5299570 Hatschek Apr 1994 A
5309908 Freidman et al. May 1994 A
5311865 Mayeux May 1994 A
5313940 Fuse et al. May 1994 A
5323776 Blakeley et al. Jun 1994 A
5329922 Atlee, III Jul 1994 A
5337744 Branigan Aug 1994 A
5339810 Ivers et al. Aug 1994 A
5343818 McCarthy et al. Sep 1994 A
5343869 Pross et al. Sep 1994 A
5348003 Caro Sep 1994 A
5348004 Hollub et al. Sep 1994 A
5349519 Kaestle Sep 1994 A
5349952 McCarthy et al. Sep 1994 A
5349953 McCarthy et al. Sep 1994 A
5351685 Potratz Oct 1994 A
5353799 Chance Oct 1994 A
5355880 Thomas et al. Oct 1994 A
5355882 Ukawa et al. Oct 1994 A
5361758 Hall et al. Nov 1994 A
5365066 Krueger, Jr. et al. Nov 1994 A
5368025 Young et al. Nov 1994 A
5368026 Swedlow et al. Nov 1994 A
5368224 Richardson et al. Nov 1994 A
5372136 Steuer et al. Dec 1994 A
5377675 Ruskewicz et al. Jan 1995 A
5385143 Aoyagi Jan 1995 A
5387122 Goldberger et al. Feb 1995 A
5390670 Centa et al. Feb 1995 A
5392777 Swedlow et al. Feb 1995 A
5398680 Polson et al. Mar 1995 A
5402777 Warring et al. Apr 1995 A
5411023 Morris, Sr. et al. May 1995 A
5411024 Thomas et al. May 1995 A
5413099 Schmidt et al. May 1995 A
5413100 Barthelemy et al. May 1995 A
5413101 Sugiura May 1995 A
5413102 Schmidt et al. May 1995 A
5417207 Young et al. May 1995 A
5421329 Casciani et al. Jun 1995 A
5425360 Nelson Jun 1995 A
5425362 Siker et al. Jun 1995 A
5427093 Ogawa et al. Jun 1995 A
5429128 Cadell et al. Jul 1995 A
5429129 Lovejoy et al. Jul 1995 A
5431159 Baker et al. Jul 1995 A
5431170 Mathews Jul 1995 A
5437275 Amundsen et al. Aug 1995 A
5438986 Disch et al. Aug 1995 A
5448991 Polson et al. Sep 1995 A
5452717 Branigan et al. Sep 1995 A
5465714 Scheuing Nov 1995 A
5469845 DeLonzor et al. Nov 1995 A
RE35122 Corenman et al. Dec 1995 E
5482034 Lewis et al. Jan 1996 A
5482036 Diab et al. Jan 1996 A
5483646 Uchikoga Jan 1996 A
5485847 Baker, Jr. Jan 1996 A
5490505 Diab et al. Feb 1996 A
5490523 Isaacson et al. Feb 1996 A
5491299 Naylor et al. Feb 1996 A
5494032 Robinson et al. Feb 1996 A
5497771 Rosenheimer Mar 1996 A
5499627 Steuer et al. Mar 1996 A
5503148 Pologe et al. Apr 1996 A
5505199 Kim Apr 1996 A
5507286 Solenberger Apr 1996 A
5517988 Gerhard May 1996 A
5520177 Ogawa et al. May 1996 A
5521851 Wei et al. May 1996 A
5522388 Ishikawa et al. Jun 1996 A
5524617 Mannheimer Jun 1996 A
5529064 Rall et al. Jun 1996 A
5533507 Potratz et al. Jul 1996 A
5551423 Sugiura Sep 1996 A
5551424 Morrison et al. Sep 1996 A
5553614 Chance Sep 1996 A
5553615 Carim et al. Sep 1996 A
5555882 Richardson et al. Sep 1996 A
5558096 Palatnik Sep 1996 A
5560355 Merchant et al. Oct 1996 A
5564417 Chance Oct 1996 A
5575284 Athan et al. Nov 1996 A
5575285 Takanashi et al. Nov 1996 A
5577500 Potratz Nov 1996 A
5582169 Oda et al. Dec 1996 A
5584296 Cui et al. Dec 1996 A
5588425 Sackner et al. Dec 1996 A
5588427 Tien Dec 1996 A
5590652 Inai Jan 1997 A
5595176 Yamaura Jan 1997 A
5596986 Goldfarb Jan 1997 A
5611337 Bukta Mar 1997 A
5617852 MacGregor Apr 1997 A
5619992 Guthrie et al. Apr 1997 A
5626140 Feldman et al. May 1997 A
5630413 Thomas et al. May 1997 A
5632272 Diab et al. May 1997 A
5632273 Suzuki May 1997 A
5634459 Gardosi Jun 1997 A
5638593 Gerhardt et al. Jun 1997 A
5638818 Diab et al. Jun 1997 A
5645059 Fein et al. Jul 1997 A
5645060 Yorkey Jul 1997 A
5645440 Tobler et al. Jul 1997 A
5660567 Nierlich et al. Aug 1997 A
5662105 Tien Sep 1997 A
5662106 Swedlow et al. Sep 1997 A
5666952 Fuse et al. Sep 1997 A
5671529 Nelson Sep 1997 A
5673692 Schulze et al. Oct 1997 A
5673693 Solenberger Oct 1997 A
5676139 Goldberger et al. Oct 1997 A
5676141 Hollub Oct 1997 A
5678544 DeLonzor et al. Oct 1997 A
5680857 Pelikan et al. Oct 1997 A
5685299 Diab et al. Nov 1997 A
5685301 Klomhaus Nov 1997 A
5687719 Sato et al. Nov 1997 A
5687722 Tien et al. Nov 1997 A
5692503 Kuenstner Dec 1997 A
5692505 Fouts Dec 1997 A
5709205 Bukta Jan 1998 A
5713355 Richardson et al. Feb 1998 A
5724967 Venkatachalam Mar 1998 A
5727547 Levinson et al. Mar 1998 A
5730124 Yamauchi Mar 1998 A
5731582 West Mar 1998 A
D393830 Tobler et al. Apr 1998 S
5743260 Chung et al. Apr 1998 A
5743263 Baker, Jr. Apr 1998 A
5746206 Mannheimer May 1998 A
5746697 Swedlow et al. May 1998 A
5752914 DeLonzor et al. May 1998 A
5755226 Carim et al. May 1998 A
5758644 Diab et al. Jun 1998 A
5760910 Lepper, Jr. et al. Jun 1998 A
5766125 Aoyagi et al. Jun 1998 A
5766127 Pologe et al. Jun 1998 A
5769785 Diab et al. Jun 1998 A
5772587 Gratton et al. Jun 1998 A
5774213 Trebino et al. Jun 1998 A
5776058 Levinson et al. Jul 1998 A
5776059 Kaestle Jul 1998 A
5779630 Fein et al. Jul 1998 A
5779631 Chance Jul 1998 A
5782237 Casciani et al. Jul 1998 A
5782756 Mannheimer Jul 1998 A
5782758 Ausec et al. Jul 1998 A
5786592 Hök Jul 1998 A
5790729 Pologe et al. Aug 1998 A
5792052 Isaacson et al. Aug 1998 A
5795292 Lewis et al. Aug 1998 A
5797841 DeLonzor et al. Aug 1998 A
5800348 Kaestle Sep 1998 A
5800349 Isaacson et al. Sep 1998 A
5803910 Potratz Sep 1998 A
5807246 Sakaguchi et al. Sep 1998 A
5807247 Merchant et al. Sep 1998 A
5807248 Mills Sep 1998 A
5810723 Aldrich Sep 1998 A
5810724 Gronvall Sep 1998 A
5813980 Levinson et al. Sep 1998 A
5817008 Rafert et al. Oct 1998 A
5817009 Rosenheimer et al. Oct 1998 A
5817010 Hibl Oct 1998 A
5818985 Merchant et al. Oct 1998 A
5820550 Polson et al. Oct 1998 A
5823950 Diab et al. Oct 1998 A
5823952 Levinson et al. Oct 1998 A
5827182 Raley et al. Oct 1998 A
5830135 Bosque et al. Nov 1998 A
5830136 DeLonzor et al. Nov 1998 A
5830137 Scharf Nov 1998 A
5830139 Abreu Nov 1998 A
5839439 Nierlich et al. Nov 1998 A
RE36000 Swedlow et al. Dec 1998 E
5842979 Jarman et al. Dec 1998 A
5842981 Larsen et al. Dec 1998 A
5842982 Mannheimer Dec 1998 A
5846190 Woehrle Dec 1998 A
5851178 Aronow Dec 1998 A
5851179 Ritson et al. Dec 1998 A
5853364 Baker, Jr. et al. Dec 1998 A
5860919 Kiani-Azarbayjany et al. Jan 1999 A
5865736 Baker, Jr. et al. Feb 1999 A
5871442 Madarasz et al. Feb 1999 A
5873821 Chance et al. Feb 1999 A
5879294 Anderson et al. Mar 1999 A
5885213 Richardson et al. Mar 1999 A
5890929 Mills et al. Apr 1999 A
5891021 Dillon et al. Apr 1999 A
5891022 Pologe Apr 1999 A
5891024 Jarman et al. Apr 1999 A
5891025 Buschmann et al. Apr 1999 A
5891026 Wang et al. Apr 1999 A
5902235 Lewis et al. May 1999 A
5910108 Solenberger Jun 1999 A
5911690 Rall Jun 1999 A
5912656 Tham et al. Jun 1999 A
5913819 Taylor et al. Jun 1999 A
5916154 Hobbs et al. Jun 1999 A
5916155 Levinson et al. Jun 1999 A
5919133 Taylor et al. Jul 1999 A
5919134 Diab Jul 1999 A
5920263 Huttenhoff et al. Jul 1999 A
5921921 Potratz et al. Jul 1999 A
5922607 Bernreuter Jul 1999 A
5924979 Swedlow et al. Jul 1999 A
5924980 Coetzee Jul 1999 A
5924982 Chin Jul 1999 A
5924985 Jones Jul 1999 A
5934277 Mortz Aug 1999 A
5934925 Tobler et al. Aug 1999 A
5940182 Lepper, Jr. et al. Aug 1999 A
5954644 Dettling et al. Sep 1999 A
5960610 Levinson et al. Oct 1999 A
5961450 Merchant et al. Oct 1999 A
5961452 Chung et al. Oct 1999 A
5964701 Asada et al. Oct 1999 A
5971930 Elghazzawi Oct 1999 A
5978691 Mills Nov 1999 A
5978693 Hamilton et al. Nov 1999 A
5983122 Jarman et al. Nov 1999 A
5987343 Kinast Nov 1999 A
5991648 Levin Nov 1999 A
5995855 Kiani et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995858 Kinast Nov 1999 A
5995859 Takahashi Nov 1999 A
5997343 Mills et al. Dec 1999 A
5999834 Wang et al. Dec 1999 A
6002952 Diab et al. Dec 1999 A
6005658 Kaluza et al. Dec 1999 A
6006120 Levin Dec 1999 A
6011985 Athan et al. Jan 2000 A
6011986 Diab et al. Jan 2000 A
6014576 Raley et al. Jan 2000 A
6018673 Chin et al. Jan 2000 A
6018674 Aronow Jan 2000 A
6022321 Amano et al. Feb 2000 A
6023541 Merchant et al. Feb 2000 A
6026312 Shemwell et al. Feb 2000 A
6026314 Amerov et al. Feb 2000 A
6031603 Fine et al. Feb 2000 A
6035223 Baker, Jr. Mar 2000 A
6036642 Diab et al. Mar 2000 A
6041247 Weckstrom et al. Mar 2000 A
6044283 Fein et al. Mar 2000 A
6047201 Jackson, III Apr 2000 A
6061584 Lovejoy et al. May 2000 A
6064898 Aldrich May 2000 A
6064899 Fein et al. May 2000 A
6067462 Diab et al. May 2000 A
6073038 Wang et al. Jun 2000 A
6078833 Hueber Jun 2000 A
6081735 Diab et al. Jun 2000 A
6081742 Amano et al. Jun 2000 A
6083157 Noller Jul 2000 A
6083172 Baker, Jr. et al. Jul 2000 A
6088607 Diab et al. Jul 2000 A
6094592 Yorkey et al. Jul 2000 A
6095974 Shemwell et al. Aug 2000 A
6104938 Huiku et al. Aug 2000 A
6112107 Hannula Aug 2000 A
6113541 Dias et al. Sep 2000 A
6115621 Chin Sep 2000 A
6120460 Abreu Sep 2000 A
6122535 Kaestle et al. Sep 2000 A
6133994 Mathews et al. Oct 2000 A
6134460 Chance Oct 2000 A
6135952 Coetzee Oct 2000 A
6144444 Haworth et al. Nov 2000 A
6144867 Walker et al. Nov 2000 A
6144868 Parker Nov 2000 A
6149481 Wang et al. Nov 2000 A
6150951 Olejniczak Nov 2000 A
6151107 Schöllermann et al. Nov 2000 A
6151518 Hayashi Nov 2000 A
6152754 Gerhardt et al. Nov 2000 A
6154667 Miura et al. Nov 2000 A
6157850 Diab et al. Dec 2000 A
6163715 Larsen et al. Dec 2000 A
6165005 Mills et al. Dec 2000 A
6173196 Delonzor et al. Jan 2001 B1
6178343 Bindszus et al. Jan 2001 B1
6181958 Steuer et al. Jan 2001 B1
6181959 Schöllermann et al. Jan 2001 B1
6184521 Coffin, IV et al. Feb 2001 B1
6188470 Grace Feb 2001 B1
6192260 Chance Feb 2001 B1
6195575 Levinson Feb 2001 B1
6198951 Kosuda et al. Mar 2001 B1
6206830 Diab et al. Mar 2001 B1
6213952 Finarov et al. Apr 2001 B1
6217523 Amano et al. Apr 2001 B1
6222189 Misner et al. Apr 2001 B1
6226539 Potratz May 2001 B1
6226540 Bernreuter et al. May 2001 B1
6229856 Diab et al. May 2001 B1
6230035 Aoyagi et al. May 2001 B1
6233470 Tsuchiya May 2001 B1
6236871 Tsuchiya May 2001 B1
6236872 Diab et al. May 2001 B1
6240305 Tsuchiya May 2001 B1
6253097 Aronow et al. Jun 2001 B1
6253098 Walker et al. Jun 2001 B1
6256523 Diab et al. Jul 2001 B1
6256524 Walker et al. Jul 2001 B1
6261236 Grimblatov Jul 2001 B1
6263221 Chance et al. Jul 2001 B1
6263222 Diab et al. Jul 2001 B1
6263223 Shepherd et al. Jul 2001 B1
6266546 Steuer et al. Jul 2001 B1
6266547 Walker et al. Jul 2001 B1
6272363 Casciani et al. Aug 2001 B1
6278522 Lepper, Jr. et al. Aug 2001 B1
6280213 Tobler et al. Aug 2001 B1
6280381 Malin et al. Aug 2001 B1
6285894 Oppelt et al. Sep 2001 B1
6285895 Ristolainen et al. Sep 2001 B1
6285896 Tobler et al. Sep 2001 B1
6298252 Kovach et al. Oct 2001 B1
6308089 Von der Ruhr et al. Oct 2001 B1
6312393 Abreu Nov 2001 B1
6321100 Parker Nov 2001 B1
6330468 Scharf Dec 2001 B1
6334065 Al-Ali et al. Dec 2001 B1
6339715 Bahr et al. Jan 2002 B1
6343223 Chin et al. Jan 2002 B1
6343224 Parker Jan 2002 B1
6349228 Kiani et al. Feb 2002 B1
6351658 Middleman et al. Feb 2002 B1
6353750 Kimura et al. Mar 2002 B1
6356774 Bernstein et al. Mar 2002 B1
6360113 Dettling Mar 2002 B1
6360114 Diab et al. Mar 2002 B1
6361501 Amano et al. Mar 2002 B1
6363269 Hanna et al. Mar 2002 B1
6370408 Merchant et al. Apr 2002 B1
6370409 Chung et al. Apr 2002 B1
6374129 Chin et al. Apr 2002 B1
6377829 Al-Ali et al. Apr 2002 B1
6381479 Norris Apr 2002 B1
6381480 Stoddar et al. Apr 2002 B1
6385471 Mortz May 2002 B1
6385821 Modgil et al. May 2002 B1
6388240 Schulz et al. May 2002 B2
6393310 Kuenster May 2002 B1
6397091 Diab et al. May 2002 B2
6397092 Norris et al. May 2002 B1
6397093 Aldrich May 2002 B1
6400971 Finarov et al. Jun 2002 B1
6400972 Fine Jun 2002 B1
6402690 Rhee et al. Jun 2002 B1
6408198 Hanna et al. Jun 2002 B1
6411832 Guthermann Jun 2002 B1
6411833 Baker, Jr. et al. Jun 2002 B1
6415236 Kobayashi et al. Jul 2002 B2
6419671 Lemberg Jul 2002 B1
6421549 Jacques Jul 2002 B1
6430423 DeLonzor et al. Aug 2002 B2
6430513 Wang et al. Aug 2002 B1
6430525 Weber et al. Aug 2002 B1
6434408 Heckel et al. Aug 2002 B1
6438399 Kurth Aug 2002 B1
6449501 Reuss Sep 2002 B1
6453183 Walker Sep 2002 B1
6453184 Hyogo et al. Sep 2002 B1
6456862 Benni Sep 2002 B2
6461305 Schnall Oct 2002 B1
6463310 Swedlow et al. Oct 2002 B1
6463311 Diab Oct 2002 B1
6466808 Chin et al. Oct 2002 B1
6466809 Riley Oct 2002 B1
6470199 Kopotic et al. Oct 2002 B1
6470200 Walker et al. Oct 2002 B2
6480729 Stone Nov 2002 B2
6487439 Skladnev et al. Nov 2002 B1
6490466 Fein et al. Dec 2002 B1
6496711 Athan et al. Dec 2002 B1
6498942 Esenaliev et al. Dec 2002 B1
6501974 Huiku Dec 2002 B2
6501975 Diab et al. Dec 2002 B2
6505060 Norris Jan 2003 B1
6505061 Larson Jan 2003 B2
6505133 Hanna et al. Jan 2003 B1
6510329 Heckel Jan 2003 B2
6510331 Williams et al. Jan 2003 B1
6512937 Blank et al. Jan 2003 B2
6515273 Al-Ali Feb 2003 B2
6519484 Lovejoy et al. Feb 2003 B1
6519486 Edgar, Jr. et al. Feb 2003 B1
6519487 Parker Feb 2003 B1
6525386 Mills et al. Feb 2003 B1
6526300 Kiani et al. Feb 2003 B1
6526301 Larsen et al. Feb 2003 B2
6541756 Schulz et al. Apr 2003 B2
6542764 Al-Ali et al. Apr 2003 B1
6544193 Abreu Apr 2003 B2
6546267 Sugiura et al. Apr 2003 B1
6549795 Chance Apr 2003 B1
6553241 Mannheimer et al. Apr 2003 B2
6553242 Sarussi Apr 2003 B1
6553243 Gurley Apr 2003 B2
6556852 Schulze et al. Apr 2003 B1
6560470 Pologe May 2003 B1
6564077 Mortara May 2003 B2
6564088 Soller et al. May 2003 B1
6571113 Fein et al. May 2003 B1
6571114 Koike et al. May 2003 B1
6574491 Elghazzawi Jun 2003 B2
6580086 Schulz et al. Jun 2003 B1
6584336 Ali et al. Jun 2003 B1
6587703 Cheng et al. Jul 2003 B2
6587704 Fine et al. Jul 2003 B1
6589172 Williams et al. Jul 2003 B2
6591122 Schmitt Jul 2003 B2
6591123 Fein et al. Jul 2003 B2
6594511 Stone et al. Jul 2003 B2
6594512 Huang Jul 2003 B2
6594513 Jobsis et al. Jul 2003 B1
6597931 Cheng et al. Jul 2003 B1
6597933 Kiani et al. Jul 2003 B2
6600940 Fein et al. Jul 2003 B1
6606509 Schmitt Aug 2003 B2
6606510 Swedlow et al. Aug 2003 B2
6606511 Ali et al. Aug 2003 B1
6606512 Muz et al. Aug 2003 B2
6615064 Aldrich Sep 2003 B1
6615065 Barrett et al. Sep 2003 B1
6618602 Levin et al. Sep 2003 B2
6622034 Gorski et al. Sep 2003 B1
6622095 Kobayashi et al. Sep 2003 B2
6628975 Fein et al. Sep 2003 B1
6631281 Kästle Oct 2003 B1
6643530 Diab et al. Nov 2003 B2
6643531 Katarow Nov 2003 B1
6647279 Pologe Nov 2003 B2
6647280 Bahr et al. Nov 2003 B2
6650917 Diab et al. Nov 2003 B2
6650918 Terry Nov 2003 B2
6654621 Palatnik et al. Nov 2003 B2
6654622 Eberhard et al. Nov 2003 B1
6654623 Kästle Nov 2003 B1
6654624 Diab et al. Nov 2003 B2
6658276 Kianl et al. Dec 2003 B2
6658277 Wasserman Dec 2003 B2
6662030 Khalil et al. Dec 2003 B2
6662033 Casciani et al. Dec 2003 B2
6665551 Suzuki Dec 2003 B1
6668182 Hubelbank Dec 2003 B2
6668183 Hicks et al. Dec 2003 B2
6671526 Aoyagi et al. Dec 2003 B1
6671528 Steuer et al. Dec 2003 B2
6671530 Chung et al. Dec 2003 B2
6671531 Al-Ali et al. Dec 2003 B2
6671532 Fudge et al. Dec 2003 B1
6675031 Porges et al. Jan 2004 B1
6678543 Diab et al. Jan 2004 B2
6681126 Solenberger Jan 2004 B2
6681128 Steuer et al. Jan 2004 B2
6681454 Modgil et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6684091 Parker Jan 2004 B2
6690958 Walker et al. Feb 2004 B1
6694160 Chin Feb 2004 B2
6697653 Hanna Feb 2004 B2
6697655 Sueppel et al. Feb 2004 B2
6697656 Al-Ali Feb 2004 B1
6697658 Al-Ali Feb 2004 B2
RE38476 Diab et al. Mar 2004 E
6699194 Diab et al. Mar 2004 B1
6699199 Asada et al. Mar 2004 B2
6701170 Stetson Mar 2004 B2
6702752 Dekker Mar 2004 B2
6707257 Norris Mar 2004 B2
6708048 Chance Mar 2004 B1
6708049 Berson et al. Mar 2004 B1
6709402 Dekker Mar 2004 B2
6711424 Fine et al. Mar 2004 B1
6711425 Reuss Mar 2004 B1
6714803 Mortz Mar 2004 B1
6714804 Al-Ali et al. Mar 2004 B2
6714805 Jeon et al. Mar 2004 B2
RE38492 Diab et al. Apr 2004 E
6719686 Coakley et al. Apr 2004 B2
6719705 Mills Apr 2004 B2
6720734 Norris Apr 2004 B2
6721584 Baker, Jr. et al. Apr 2004 B2
6721585 Parker Apr 2004 B1
6725074 Kästle Apr 2004 B1
6725075 Al-Ali Apr 2004 B2
6731963 Finarov et al. May 2004 B2
6731967 Turcott May 2004 B1
6735459 Parker May 2004 B2
6745060 Diab et al. Jun 2004 B2
6745061 Hicks et al. Jun 2004 B1
6748253 Norris et al. Jun 2004 B2
6748254 O'Neill et al. Jun 2004 B2
6754515 Pologe Jun 2004 B1
6754516 Mannheimer Jun 2004 B2
6760607 Al-Ali Jul 2004 B2
6760609 Jacques Jul 2004 B2
6760610 Tscupp et al. Jul 2004 B2
6763255 DeLonzor et al. Jul 2004 B2
6763256 Kimball et al. Jul 2004 B2
6770028 Ali et al. Aug 2004 B1
6771994 Kiani et al. Aug 2004 B2
6773397 Kelly Aug 2004 B2
6778923 Norris et al. Aug 2004 B2
6780158 Yarita Aug 2004 B2
6785568 Chance Aug 2004 B2
6792300 Diab et al. Sep 2004 B1
6793654 Lemberg Sep 2004 B2
6801797 Mannheimer et al. Oct 2004 B2
6801798 Geddes et al. Oct 2004 B2
6801799 Mendelson Oct 2004 B2
6801802 Sitzman et al. Oct 2004 B2
6802812 Walker et al. Oct 2004 B1
6805673 Dekker Oct 2004 B2
6810277 Edgar, Jr. et al. Oct 2004 B2
6813511 Diab et al. Nov 2004 B2
6816741 Diab Nov 2004 B2
6819950 Mills Nov 2004 B2
6822564 Al-Ali Nov 2004 B2
6825619 Norris Nov 2004 B2
6826419 Diab et al. Nov 2004 B2
6829496 Nagai et al. Dec 2004 B2
6830711 Mills et al. Dec 2004 B2
6836679 Baker, Jr. et al. Dec 2004 B2
6839579 Chin Jan 2005 B1
6839580 Zonios et al. Jan 2005 B2
6839582 Heckel Jan 2005 B2
6839659 Tarassenko et al. Jan 2005 B2
6842635 Parker Jan 2005 B1
6845256 Chin et al. Jan 2005 B2
6850787 Weber et al. Feb 2005 B2
6850788 Al-Ali Feb 2005 B2
6850789 Schweitzer, Jr. et al. Feb 2005 B2
6861639 Al-Ali Mar 2005 B2
6863652 Huang et al. Mar 2005 B2
6865407 Kimball et al. Mar 2005 B2
6873865 Steuer et al. Mar 2005 B2
6879850 Kimball Apr 2005 B2
6882874 Huiku Apr 2005 B2
6889153 Dietiker May 2005 B2
6898452 Al-Ali et al. May 2005 B2
6909912 Melker et al. Jun 2005 B2
6912413 Rantala et al. Jun 2005 B2
6916289 Schnall Jul 2005 B2
6920345 Al-Ali et al. Jul 2005 B2
6931269 Terry Aug 2005 B2
6934570 Kiani et al. Aug 2005 B2
6939307 Dunlop Sep 2005 B1
6941162 Fudge et al. Sep 2005 B2
6947781 Asada et al. Sep 2005 B2
6949081 Chance Sep 2005 B1
6950687 Al-Ali Sep 2005 B2
6961598 Diab Nov 2005 B2
6963767 Rantala et al. Nov 2005 B2
6971580 DeLonzor et al. Dec 2005 B2
6983178 Fine et al. Jan 2006 B2
6985763 Boas et al. Jan 2006 B2
6985764 Mason et al. Jan 2006 B2
6990426 Yoon et al. Jan 2006 B2
6992751 Al-Ali Jan 2006 B2
6992772 Block et al. Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6993372 Fine et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
7003338 Weber et al. Feb 2006 B2
7003339 Diab et al. Feb 2006 B2
7006855 Sarussi Feb 2006 B1
7006856 Baker, Jr. et al. Feb 2006 B2
7016715 Stetson Mar 2006 B2
7020507 Scharf et al. Mar 2006 B2
7024233 Ali et al. Apr 2006 B2
7024235 Melker et al. Apr 2006 B2
7025728 Ito et al. Apr 2006 B2
7027849 Al-Ali et al. Apr 2006 B2
7027850 Wasserman Apr 2006 B2
7035697 Brown Apr 2006 B1
7039449 Al-Ali May 2006 B2
7043289 Fine et al. May 2006 B2
7047055 Boaz et al. May 2006 B2
7047056 Hannula et al. May 2006 B2
7048687 Reuss et al. May 2006 B1
7060035 Wasserman et al. Jun 2006 B2
7062307 Norris et al. Jun 2006 B2
7067893 Mills et al. Jun 2006 B2
7072701 Chen et al. Jul 2006 B2
7072702 Edgar, Jr. et al. Jul 2006 B2
7079880 Stetson Jul 2006 B2
7085597 Fein et al. Aug 2006 B2
7096054 Adbul-Hafiz et al. Aug 2006 B2
7107088 Aceti Sep 2006 B2
7113815 O'Neil et al. Sep 2006 B2
7123950 Mannheimer Oct 2006 B2
7127278 Melker et al. Oct 2006 B2
7130671 Baker, Jr. et al. Oct 2006 B2
7132641 Schulz et al. Nov 2006 B2
7133711 Chernoguz et al. Nov 2006 B2
7139599 Terry Nov 2006 B2
7142901 Kiani et al. Nov 2006 B2
7162288 Nordstrom Jan 2007 B2
7190987 Lindekugel et al. Mar 2007 B2
7198778 Achilefu et al. Apr 2007 B2
7209775 Bae et al. Apr 2007 B2
7215984 Diab et al. May 2007 B2
7225006 Al-Ali et al. May 2007 B2
7236811 Schmitt Jun 2007 B2
7236881 Liu et al. Jun 2007 B2
7248910 Li et al. Jul 2007 B2
7254433 Diab et al. Aug 2007 B2
7254434 Schulz et al. Aug 2007 B2
7263395 Chan et al. Aug 2007 B2
7272426 Scmid Sep 2007 B2
7280858 Al-Ali et al. Oct 2007 B2
7295866 Al-Ali et al. Nov 2007 B2
7305262 Brodnick et al. Dec 2007 B2
7315753 Baker, Jr. et al. Jan 2008 B2
7428432 Ali et al. Sep 2008 B2
7457652 Porges et al. Nov 2008 B2
20010005773 Larsen et al. Jun 2001 A1
20010020122 Steuer et al. Sep 2001 A1
20010021803 Blank et al. Sep 2001 A1
20010039376 Steuer et al. Nov 2001 A1
20010044700 Kobayashi et al. Nov 2001 A1
20010051767 Williams et al. Dec 2001 A1
20020026106 Khalil et al. Feb 2002 A1
20020026109 Diab et al. Feb 2002 A1
20020028990 Shepherd et al. Mar 2002 A1
20020035318 Mannheimer et al. Mar 2002 A1
20020038078 Ito Mar 2002 A1
20020038079 Steuer et al. Mar 2002 A1
20020042558 Mendelson Apr 2002 A1
20020049389 Abreu Apr 2002 A1
20020062071 Diab et al. May 2002 A1
20020068859 Knopp Jun 2002 A1
20020111748 Kobayashi et al. Aug 2002 A1
20020128544 Diab et al. Sep 2002 A1
20020133067 Jackson, III Sep 2002 A1
20020133068 Huiku Sep 2002 A1
20020156354 Larson Oct 2002 A1
20020161287 Schmitt Oct 2002 A1
20020161290 Chance Oct 2002 A1
20020165439 Schmitt Nov 2002 A1
20020173706 Takatani Nov 2002 A1
20020173709 Fine et al. Nov 2002 A1
20020190863 Lynn Dec 2002 A1
20020198442 Rantala et al. Dec 2002 A1
20020198443 Ting Dec 2002 A1
20030018243 Gerhardt et al. Jan 2003 A1
20030023140 Chance Jan 2003 A1
20030036690 Geddes et al. Feb 2003 A1
20030045785 Diab et al. Mar 2003 A1
20030055324 Wasserman Mar 2003 A1
20030060693 Monfre et al. Mar 2003 A1
20030073889 Keilbach et al. Apr 2003 A1
20030073890 Hanna Apr 2003 A1
20030100840 Sugiura et al. May 2003 A1
20030132495 Mills et al. Jul 2003 A1
20030135099 Al-Ali Jul 2003 A1
20030139687 Abreu Jul 2003 A1
20030144584 Mendelson Jul 2003 A1
20030162414 Schulz et al. Aug 2003 A1
20030171662 O'Connor et al. Sep 2003 A1
20030176776 Huiku Sep 2003 A1
20030181799 Lindekugel et al. Sep 2003 A1
20030187337 Tarassenko et al. Oct 2003 A1
20030195402 Fein et al. Oct 2003 A1
20030197679 Ali et al. Oct 2003 A1
20030212316 Leiden et al. Nov 2003 A1
20030220548 Schmitt Nov 2003 A1
20030220576 Diab Nov 2003 A1
20030225323 Kiani et al. Dec 2003 A1
20030225337 Scharf et al. Dec 2003 A1
20030236452 Melker et al. Dec 2003 A1
20030236647 Yoon et al. Dec 2003 A1
20040006261 Swedlow et al. Jan 2004 A1
20040010188 Wasserman et al. Jan 2004 A1
20040024297 Chen et al. Feb 2004 A1
20040024326 Yeo et al. Feb 2004 A1
20040034293 Kimball Feb 2004 A1
20040039272 Abdul-Hafiz et al. Feb 2004 A1
20040039273 Terry Feb 2004 A1
20040054269 Rantala et al. Mar 2004 A1
20040054270 Pewzner et al. Mar 2004 A1
20040054291 Schulz et al. Mar 2004 A1
20040059209 Al-Ali et al. Mar 2004 A1
20040059210 Stetson Mar 2004 A1
20040064020 Diab et al. Apr 2004 A1
20040068164 Diab et al. Apr 2004 A1
20040087846 Wasserman May 2004 A1
20040092805 Yarita May 2004 A1
20040097797 Porges et al. May 2004 A1
20040098009 Boecker et al. May 2004 A1
20040107065 Al-Ali et al. Jun 2004 A1
20040116788 Chernoguz et al. Jun 2004 A1
20040116789 Boaz et al. Jun 2004 A1
20040117891 Hannula et al. Jun 2004 A1
20040122300 Boas et al. Jun 2004 A1
20040122302 Mason et al. Jun 2004 A1
20040127779 Steuer et al. Jul 2004 A1
20040133087 Ali et al. Jul 2004 A1
20040133088 Al-Ali et al. Jul 2004 A1
20040138538 Stetson Jul 2004 A1
20040138540 Baker, Jr. et al. Jul 2004 A1
20040143172 Fudge et al. Jul 2004 A1
20040147821 Al-Ali et al. Jul 2004 A1
20040147822 Al-Ali et al. Jul 2004 A1
20040147823 Kiani et al. Jul 2004 A1
20040147824 Diab et al. Jul 2004 A1
20040152965 Diab et al. Aug 2004 A1
20040158134 Diab et al. Aug 2004 A1
20040158135 Baker, Jr. et al. Aug 2004 A1
20040162472 Berson et al. Aug 2004 A1
20040171920 Mannheimer et al. Sep 2004 A1
20040171948 Terry Sep 2004 A1
20040176670 Takamura et al. Sep 2004 A1
20040176671 Fine et al. Sep 2004 A1
20040181133 Al-Ali et al. Sep 2004 A1
20040181134 Baker, Jr. et al. Sep 2004 A1
20040186358 Chernow et al. Sep 2004 A1
20040199063 O'Neil et al. Oct 2004 A1
20040204636 Diab et al. Oct 2004 A1
20040204637 Diab et al. Oct 2004 A1
20040204638 Diab et al. Oct 2004 A1
20040204639 Casciani et al. Oct 2004 A1
20040204865 Lee et al. Oct 2004 A1
20040210146 Diab et al. Oct 2004 A1
20040215069 Mannheimer Oct 2004 A1
20040230106 Schmitt et al. Nov 2004 A1
20040230107 Asada et al. Nov 2004 A1
20040230108 Melker et al. Nov 2004 A1
20040236196 Diab et al. Nov 2004 A1
20040242980 Kiani et al. Dec 2004 A1
20040249252 Fine et al. Dec 2004 A1
20040257557 Block et al. Dec 2004 A1
20040260161 Melker et al. Dec 2004 A1
20040267103 Li et al. Dec 2004 A1
20040267104 Hannula et al. Dec 2004 A1
20040267140 Ito et al. Dec 2004 A1
20050004479 Townsend et al. Jan 2005 A1
20050010092 Weber et al. Jan 2005 A1
20050020887 Goldberg Jan 2005 A1
20050020894 Norris et al. Jan 2005 A1
20050033128 Ali et al. Feb 2005 A1
20050033129 Edgar, Jr. et al. Feb 2005 A1
20050043599 O'Mara Feb 2005 A1
20050043600 Diab et al. Feb 2005 A1
20050049470 Terry Mar 2005 A1
20050049471 Aceti Mar 2005 A1
20050065417 Ali et al. Mar 2005 A1
20050075550 Lindekugel Apr 2005 A1
20050080323 Kato Apr 2005 A1
20050101850 Parker May 2005 A1
20050113656 Chance May 2005 A1
20050168722 Forstner et al. Aug 2005 A1
20050177034 Beaumont Aug 2005 A1
20050192488 Bryenton et al. Sep 2005 A1
20050197548 Dietiker Sep 2005 A1
20050203357 Debreczeny et al. Sep 2005 A1
20050228248 Dietiker Oct 2005 A1
20050267346 Faber et al. Dec 2005 A1
20050277819 Kiani et al. Dec 2005 A1
20050283059 Iyer et al. Dec 2005 A1
20060009688 Lamego et al. Jan 2006 A1
20060015021 Cheng Jan 2006 A1
20060020181 Schmitt Jan 2006 A1
20060025660 Swedlow et al. Feb 2006 A1
20060030763 Mannheimer et al. Feb 2006 A1
20060030764 Porges et al. Feb 2006 A1
20060052680 Diab Mar 2006 A1
20060058594 Ishizuka et al. Mar 2006 A1
20060058683 Chance Mar 2006 A1
20060064024 Schnall Mar 2006 A1
20060084852 Mason et al. Apr 2006 A1
20060089547 Sarussi Apr 2006 A1
20060106294 Maser et al. May 2006 A1
20060161054 Reuss et al. Jul 2006 A1
20060195028 Hannula et al. Aug 2006 A1
20060224058 Mannheimer Oct 2006 A1
20060224059 Swedlow et al. Oct 2006 A1
20060247501 Ali Nov 2006 A1
20060258921 Addison et al. Nov 2006 A1
20060258926 Ali et al. Nov 2006 A1
20070032710 Raridan et al. Feb 2007 A1
20070032712 Raridan et al. Feb 2007 A1
20070032715 Eghbal et al. Feb 2007 A1
20070073126 Raridan, Jr. Mar 2007 A1
20070112260 Diab et al. May 2007 A1
20080039701 Ali et al. Feb 2008 A1
Foreign Referenced Citations (30)
Number Date Country
69123448 May 1997 DE
0 221 357 May 1987 EP
0352923 Jan 1990 EP
0 571 225 Nov 1993 EP
0 571 225 Nov 1993 EP
0630203 Dec 1994 EP
1491135 Dec 2004 EP
3170866 Jul 1991 JP
3238813 Oct 1991 JP
4332536 Nov 1992 JP
6154177 Jun 1994 JP
7124138 May 1995 JP
7136150 May 1995 JP
2003194714 Jul 2003 JP
2003210438 Jul 2003 JP
2004008572 Jan 2004 JP
2004113353 Apr 2004 JP
2004194908 Jul 2004 JP
2004248819 Sep 2004 JP
2004290545 Oct 2004 JP
WO9101678 Feb 1991 WO
WO9309711 May 1993 WO
WO9423643 Oct 1994 WO
WO9516387 Jun 1995 WO
WO9843071 Oct 1998 WO
WO9932030 Jul 1999 WO
WO0021438 Apr 2000 WO
WO 0061000 Oct 2000 WO
WO0059374 Oct 2000 WO
WO03011127 Feb 2003 WO
Related Publications (1)
Number Date Country
20060030764 A1 Feb 2006 US
Provisional Applications (1)
Number Date Country
60129170 Apr 1999 US
Continuations (2)
Number Date Country
Parent 10712895 Nov 2003 US
Child 11241635 US
Parent 09545170 Apr 2000 US
Child 10712895 US